Sign Up For Future Updates
Renal Cell CarcinomaImmune reactivity in patients with Renal cell carcinoma (RCC) has been much studied. The Ludwig Institute for Cancer Research in New York has intensively researched this field and determined that RCC is a potently immunogenic disease. For example a SEREX study (www.cancerimmunity.org/SEREX/introduction.htm) at the LICR revealed a total of 65 known and novel tumor antigens to be reactive to RCC patient serum. Of these a core panel of 12 antigens emerged as highly significant since antibodies to this panel were absent in normal serum whereas 72% of RCC patients (23/32) were found to have antibodies to at least one antigen in this panel [1]. Studies elsewhere have also revealed RCC tumor antigens and some of these have been proposed as drug targets in the treatment of this disease [2].The study of patient immunity to tumor antigens is increasingly recognized as a valuable tool in predicting and monitoring patient responses to oncology drugs. Indeed the use of irRC (immune related response criteria) as an alternative or supplemental tool in evaluating patient clinical responses to immunotherapy has been formally advocated [3] and is likely to be adopted in non-immunotherapy drug classes.Serametrix has developed a multiplex assay for the study of serum antibodies to RCC antigens. The assay, which utilizes a protein microarray of 28 full-length human RCC tumor associated antigens, is offered to the pharmaceutical industry to aid drug development. In this assay Serametrix analyzes serum from clinical trials for a novel RCC therapy. For more information and an up-to-date list of the current antigens included in the assay, contact us today by emailing info@serametrix.com.
References: References:[1] Scanlan, Lloyd Old et al. (1999). Antigens recognized by autologous antibody in patients with renal-cell carcinoma Int. J. Cancer: 83, 456–464[2] Schmidt et al (2008) Vaccinations with RNA coding for tumor associated antigens in advanced RCC patients—A phase I/II study Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition).Vol 26, No 15S[3] Ribas et al (2009) Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy? Clin Cancer Res December 1, 2009 15:7116-7118
|